Patient demographic and transplant characteristics
Factor . | Fluconazole; n = 148 . | Itraconazole; n = 151 . |
|---|---|---|
| Age, n (%) | ||
| 20 y or younger | 3 (2) | 2 (1) |
| Older than 20 y | 145 (98) | 149 (99) |
| Sex, n (%) | ||
| Male | 81 (55) | 75 (50) |
| Female | 67 (45) | 76 (50) |
| Disease risk group (%)* | ||
| Low | 47 (32) | 43 (28) |
| Intermediate | 74 (50) | 74 (49) |
| High | 27 (18) | 34 (23) |
| Transplant type (%) | ||
| HLA MR | 82 (55) | 79 (52) |
| HLA MM/URD | 66 (45) | 72 (48) |
| Median neutrophil engraftment, d (range)† | 19 (10-35) | 19 (9-46) |
| Acute GVHD (%)‡ | ||
| Grades 0-I | 22 (18) | 30 (24) |
| Grades II-IV | 99 (82) | 93 (76) |
Factor . | Fluconazole; n = 148 . | Itraconazole; n = 151 . |
|---|---|---|
| Age, n (%) | ||
| 20 y or younger | 3 (2) | 2 (1) |
| Older than 20 y | 145 (98) | 149 (99) |
| Sex, n (%) | ||
| Male | 81 (55) | 75 (50) |
| Female | 67 (45) | 76 (50) |
| Disease risk group (%)* | ||
| Low | 47 (32) | 43 (28) |
| Intermediate | 74 (50) | 74 (49) |
| High | 27 (18) | 34 (23) |
| Transplant type (%) | ||
| HLA MR | 82 (55) | 79 (52) |
| HLA MM/URD | 66 (45) | 72 (48) |
| Median neutrophil engraftment, d (range)† | 19 (10-35) | 19 (9-46) |
| Acute GVHD (%)‡ | ||
| Grades 0-I | 22 (18) | 30 (24) |
| Grades II-IV | 99 (82) | 93 (76) |
HLA MR indicates human leukocyte antigen matched related; HLA MM/URD, human leukocyte antigen mismatched or unrelated donor.
Low-risk groups include chronic myelogenous leukemia (CML, chronic phase) and aplastic anemia; intermediate disease risk groups include CML in accelerated phase myelodysplastic syndromes (MDS) and hematologic malignancies in remission; and high-risk groups include CML in blast crisis, hematologic malignancies in other than 1st remission, multiple myeloma, and MDS-RAEBT (refractory anemia with excess blasts in transition).
Day of neutrophil engraftment was defined as third consecutive day on which the absolute neutrophil count exceeded 0.5 × 109/L. Median was calculated from 145 patients in each arm who achieved engraftment.
Calculated from 244 patients who had GVHD grades available.